{"classes":[{"categories":[{"measurements":[{"comment":"There was only 1 participant with response.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"13.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ewing sarcoma.","id":"OG000","title":"Cohort 1"},{"description":"Participants with non-rhabdomyosarcoma soft tissue sarcoma.","id":"OG001","title":"Cohort 5"},{"description":"Participants with osteosarcoma.","id":"OG002","title":"Cohort 6"},{"description":"Participants with rhabdomyosarcoma.","id":"OG003","title":"Cohort 7"},{"description":"Participants with wilms tumor.","id":"OG004","title":"Cohort 8"},{"description":"Participants with other tumor types with documented PD-L1 expression.","id":"OG005","title":"Cohort 9"},{"description":"Participants with other tumor types without documented PD-L1 expression.","id":"OG006","title":"Cohort 10"},{"description":"Participants with rhabdoid tumor.","id":"OG007","title":"Cohort 11"},{"description":"Participants with atypical teratoid rhabdoid tumor.","id":"OG008","title":"Cohort 12"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"DOR as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors","type":"SECONDARY","unitOfMeasure":"Months"}